Medtronic price target raised to $105 from $104 at Barclays

Barclays raised the firm’s price target on Medtronic to $105 from $104 and keeps an Overweight rating on the shares. The analyst expects the company’s fiscal 2025 second half to feature accelerating earnings growth driven by a broad pipeline of innovative new products and easing currency hedging expense. The firm thinks these dynamics will drive increased investor interest and improving stock performance over the next 12 months.